In this article, we discuss the 5 best healthcare stocks to buy according to Greg Martinez’s Parkman Healthcare Partners. If you want our detailed analysis of these stocks, go directly to the 10 Best Healthcare Stocks to Buy According to Greg Martinez’s Parkman Healthcare Partners.
5. IQVIA Holdings Inc. (NYSE:IQV)
Parkman Healthcare Partners’ Stake Value: $16,736,000
Percentage of Parkman Healthcare Partners’ 13F Portfolio: 4.23%
Number of Hedge Fund Holders: 66
IQVIA Holdings Inc. (NYSE:IQV) is an American multinational health information technology company engaged in extensive clinical research to improve the healthcare system and create breakthrough solutions that enhance patient care. Greg Martinez, via Parkman Healthcare Partners, holds a $16.73 million position in IQVIA Holdings Inc. (NYSE:IQV), which accounts for 4.23% of the firm’s total Q3 investments.
As of September, 66 hedge funds tracked by Insider Monkey were long IQVIA Holdings Inc. (NYSE:IQV), with Thomas Steyer’s Farallon Capital being the largest shareholder, with over 2.7 million shares valued at $647.65 million.
IQVIA Holdings Inc. (NYSE:IQV) reported Q3 earnings on October 21, with EPS for the quarter being $2.17, topping estimates by $0.05. The quarterly revenue was up 21.72% from the prior-year quarter at $3.39 billion, outperforming estimated revenue by $40.36 million.
Mizuho analyst Ann Hynes on November 18 raised the price target on IQVIA Holdings Inc. (NYSE:IQV) to $290 from $282 and kept a Buy rating on the shares, stating that the revenue and earnings growth potential at IQVIA Holdings Inc. (NYSE:IQV) is strong.
4. United Therapeutics Corporation (NASDAQ:UTHR)
Parkman Healthcare Partners’ Stake Value: $17,410,000
Percentage of Parkman Healthcare Partners’ 13F Portfolio: 4.40%
Number of Hedge Fund Holders: 52
United Therapeutics Corporation (NASDAQ:UTHR) disclosed Q3 results on November 3. EPS for the period amounted to $4.16, beating estimates by $0.07. The quarterly revenue equaled $444.70 million, jumping 17% on a year-over-year basis, and exceeding estimates by $23.25 million. United Therapeutics Corporation (NASDAQ:UTHR) is a biotech company focused on creating life-enhancing technologies for patients with lung diseases and for those individuals in need of organ manufacturing.
Greg Martinez, via Parkman Healthcare Partners, holds 94,324 shares in United Therapeutics Corporation (NASDAQ:UTHR), worth $17.41 million, representing 4.4% of the firm’s Q3 portfolio. Jim Simons’ Renaissance Technologies is the leading United Therapeutics Corporation (NASDAQ:UTHR) stakeholder, owning over 3 million shares worth $559 million.
Insider Monkey tracks the movement of 867 hedge funds as of Q3 2021, of which 52 funds were bullish on United Therapeutics Corporation (NASDAQ:UTHR), with stakes worth $2.17 billion. This is comparable to 45 funds in the preceding quarter, with a total stake value of $2.33 billion.
3. Avantor, Inc. (NYSE:AVTR)
Parkman Healthcare Partners’ Stake Value: $17,996,000
Percentage of Parkman Healthcare Partners’ 13F Portfolio: 4.55%
Number of Hedge Fund Holders: 53
Avantor, Inc. (NYSE:AVTR) is a global provider of medical equipment, clinical kits, lab and production services, and clinical services to the healthcare, biopharmaceutical, and advanced technologies and applied materials industries. Greg Martinez, as of the third quarter, holds a stake worth approximately $18 million in Avantor, Inc. (NYSE:AVTR), which accounts for 4.55% of his stock portfolio.
Dan Loeb’s Third Point is the largest Avantor, Inc. (NYSE:AVTR) stakeholder, as of Q3 2021, with 10.8 million shares worth $441.7 million. Overall, 53 hedge funds were bullish on Avantor, Inc. (NYSE:AVTR) in the third quarter, up from 44 funds in the previous quarter.
Avantor, Inc. (NYSE:AVTR), on October 28, posted its Q3 earnings. EPS for the quarter equaled $0.35, beating estimated EPS by $0.03. Revenue in the period amounted to $1.83 billion, missing estimated revenue by -$6.55 million.
JPMorgan analyst Tycho Peterson reinstated coverage of Avantor, Inc. (NYSE:AVTR) with an Overweight rating and price target of $55, up from $45 on November 22. According to the analyst, the company has successfully diversified revenues and driven margin expansion with recent acquisitions.
2. Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Parkman Healthcare Partners’ Stake Value: $23,516,000
Percentage of Parkman Healthcare Partners’ 13F Portfolio: 5.94%
Number of Hedge Fund Holders: 36
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a clinical-stage biopharmaceutical company engaged in developing drugs for immuno-inflammatory diseases. Greg Martinez, via Parkman Healthcare Partners, holds 1.3 million shares in Aclaris Therapeutics, Inc. (NASDAQ:ACRS), worth $23.5 million, representing 5.94% of the firm’s Q3 portfolio.
As of Q3 2021, Rock Springs Capital Management is the leading Aclaris Therapeutics, Inc. (NASDAQ:ACRS) stakeholder, with 3.8 million shares amounting to $68.45 million. Overall, 36 hedge funds were long Aclaris Therapeutics, Inc. (NASDAQ:ACRS) in the third quarter, with the total stake value exceeding $470 million.
On November 2, the Q3 EPS for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) totaled -$0.35, missing EPS estimates by -$0.07. The $1.66 million revenue was up 14.49% year-over-year, but failed to meet analysts’ revenue estimates by -$111,670.
1. DexCom, Inc. (NASDAQ:DXCM)
Parkman Healthcare Partners’ Stake Value: $24,859,000
Percentage of Parkman Healthcare Partners’ 13F Portfolio: 6.28%
Number of Hedge Fund Holders: 53
DexCom, Inc. (NASDAQ:DXCM) is the largest holding in Greg Martinez’s Parkman Healthcare Advisors’ Q3 portfolio, with the firm owning 45,458 shares in DexCom, Inc. (NASDAQ:DXCM), worth $24.85 million, representing 6.28% of the total investments for the third quarter. DexCom, Inc. (NASDAQ:DXCM) is a California-based manufacturer of glucose monitoring systems for diabetes management.
DexCom, Inc. (NASDAQ:DXCM), on October 28, announced Q3 earnings results. EPS for the third quarter came in at $0.89, beating estimates by $0.24. The $650.20 million revenue jumped almost 30% from the preceding-year quarter, exceeding estimated revenue by $33.09 million.
Piper Sandler analyst Matt O’Brien on November 3 raised the price target on DexCom, Inc. (NASDAQ:DXCM) to $750 from $675 and kept an Overweight rating on the shares.
A total of 53 hedge funds monitored by Insider Monkey as of Q3 2021 reported owning stakes in DexCom, Inc. (NASDAQ:DXCM), worth $1.78 billion, with Stephen Mandel’s Lone Pine Capital being the biggest company stakeholder.
Here is what Carillon Tower Advisers has to say about DexCom, Inc. (NASDAQ:DXCM) in their Q4 2020 investor letter:
“DexCom, a developer and manufacturer of continuous glucose monitors (CGMs) for people with diabetes, saw its share price suffer in the quarter after an announcement from its largest competitor that it had finally developed a CGM that appears to be competitive with Dexcom’s flagship G6 sensor. Until the competitive dynamics are sorted out, we feel as though the firm’s shares could remain range-bound, leading us to exit the position.”
You can also take a look at Frank Fu’s CaaS Capital Portfolio: Didi, Mastercard and More and Retirement Stock Portfolio: 10 Safe Tech Stocks To Consider.
